The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.
The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
The study also found that younger African-Americans who received genomic testing were more likely to be treated with chemotherapy even with low assay scores.
CMS issued its final Clinical Laboratory Fee Schedule for 2016 yesterday, shifting to gapfill rather crosswalk new codes as initially proposed for MAAAs.
Researchers considered the management impact of multigene panel results for more than 1,000 BRCA1/2 mutation-free women referred for hereditary breast and ovarian cancer testing.
This article has been updated to clarify CMS's initial determination on the reimbursement process for AMA's new molecular pathology test codes.
NEW YORK (GenomeWeb News) - Transgenomic today said that it has signed a definitive agreement to acquire the global rights to a multi-gene prognostic test for scoliosis from Axial Biotech.
The funding is part of an initiative led by the UK's Technology Strategy Board to develop tools for tumor profiling and data capture.
The deal is a "strategic move into gastrointestinal diagnostics," and will accelerate development of diagnostics in oncology and possibly other therapeutic areas.
The company said that Aetna has determined that AlloMap is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.